<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03115307</url>
  </required_header>
  <id_info>
    <org_study_id>R16171M</org_study_id>
    <secondary_id>2016-002321-11</secondary_id>
    <nct_id>NCT03115307</nct_id>
  </id_info>
  <brief_title>Luteal Phase Support in Insemination Cycles</brief_title>
  <official_title>A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal Phase in the Insemination Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized trial with 242 IUI cycles. Patients are randomized in
      two groups including 121 patients in each group. In the first group, the patients will be
      treated with triptoreline (Gonapeptyl®) in their luteal phase. As for the other group, the
      patients will undergo the luteal phase without any supportive medication. This study is going
      to clarify the role of the gonadotropin agonist (triptoreline, Gonapeptyl®) as a luteal phase
      supporter. The benefit of the treatment is measured by the numbers in the live birth and
      clinical pregnancy rates.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>At possible delivery (about 40 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>After two weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>During subsequent about 40 weeks of pregnancy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Gonapeptyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the intervention group the patient will get the advice to using triptoreline (Gonapeptyl®) in the eight day after the injection of hCG (Pregnyl®) in the insemination cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control group, there are no luteal phase medications in the insemination cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin</intervention_name>
    <description>Triptoreline 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.</description>
    <arm_group_label>Gonapeptyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Patients with ovarian stimulation cycles preparing to insemination

          -  Patients with medical ovarian stimulation protocols including GnRH agonist, aromatase
             inhibitors and different combinations of GnRH agonists and aromatase inhibitors are
             included

          -  Patient's willingness to participate in the study

        Exclusion Criteria:

          -  - Failure in the ovarian stimulation cycle

          -  Failures in executing the insemination

          -  Failures in giving the sperm sample

          -  Major troubles in sperm parameters leading to an inadequate sample to accomplish
             intrauterine insemination

          -  Patients with primarily planned progesterone luteal support
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Tinkanen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helena Tinkanen</last_name>
    <email>helena.tinkanen@pshp.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Riikka Leppänen</last_name>
    <email>riikka.leppanen@pshp.gi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Tinkanen, M.D., Ph.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Riikka Leppänen, M.D.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insemination</keyword>
  <keyword>Luteal phase support</keyword>
  <keyword>Gonadotropin-releasing hormone agonist</keyword>
  <keyword>Triptoreline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

